[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100524446":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":48,"centralContacts":52,"locations":59,"responsibleParty":75,"collaborators":57,"id":78,"slug":79,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":57,"eligibilityCriteria":84,"healthyVolunteers":80,"sex":85,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":57,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":97,"overallStatus":61,"whyStopped":57,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Tianjin Medical University General Hospital","OTHER",[8,14,20,25],{"label":9,"type":10,"description":11,"interventionNames":12},"Group of patients undergoing gastroenteroscopies with normal saline","PLACEBO_COMPARATOR","Patients undergoing gastroenteroscopies were given propofol 2-3mg\u002Fkg and 10ml 0.9% saline before the procedure began",[13],"Drug: normal saline",{"label":15,"type":16,"description":17,"interventionNames":18},"Group of patients undergoing gastroenteroscopies with esketamine","ACTIVE_COMPARATOR","Patients undergoing gastroenteroscopies were given propofol 2 to 3mg\u002Fkg and esketamine 0.2mg\u002Fkg before the procedure began",[19],"Drug: Esketamine",{"label":21,"type":16,"description":22,"interventionNames":23},"Group of patients undergoing gastroenteroscopies with remimazolam","Patients undergoing gastroenteroscopies were given propofol 2 to 3mg\u002Fkg and remimazolam 0.15mg\u002Fkg before the procedure began",[24],"Drug: Remimazolam",{"label":26,"type":16,"description":27,"interventionNames":28},"Group of patients undergoing gastroenteroscopies with remimazolam and esketamine","Patients undergoing gastroenteroscopies were given propofol 2 to 3mg\u002Fkg， esketamine 0.2mg\u002Fkg and remimazolam 0.15mg\u002Fkg before the procedure began",[29],"Drug: Esketamine and remimazolam",[31,36,40,44],{"type":32,"name":33,"description":17,"armGroupLabels":34,"otherNames":35},"DRUG","Esketamine",[15],[15],{"type":32,"name":37,"description":22,"armGroupLabels":38,"otherNames":39},"Remimazolam",[21],[22],{"type":32,"name":41,"description":22,"armGroupLabels":42,"otherNames":43},"Esketamine and remimazolam",[26],[27],{"type":32,"name":45,"description":11,"armGroupLabels":46,"otherNames":47},"normal saline",[9],[9],[49],{"name":50,"affiliation":5,"role":51},"Guolin Wang","STUDY_DIRECTOR",[53],{"name":54,"role":55,"phone":56,"phoneExt":57,"email":58},"Guolin Wang, MD","CONTACT","+8615822855556",null,"wangguolinghad@hotmail.com",[60],{"facility":5,"status":61,"city":62,"state":57,"zip":63,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":71,"contacts":72},"RECRUITING","Tianjin","300052","China","CN",{"type":67,"coordinates":68},"Point",[69,70],117.17667,39.14222,{"lat":70,"lon":69},[73],{"name":50,"role":55,"phone":74,"phoneExt":57,"email":57},"+8618604755166",{"type":76,"investigatorFullName":50,"investigatorTitle":77,"investigatorAffiliation":5,"oldNameTitle":57,"oldOrganization":57},"PRINCIPAL_INVESTIGATOR","Professor","100524446","esketamine-combined-with-remimazolam-on-postoperative-sleep-disturbance-and-anxiety-in-patients-100524446",false,"NCT06108830","Esketamine Combined With Remimazolam on Postoperative Sleep Disturbance and Anxiety in Patients","Effect of Esketamine Combined With Remimazolam on Postoperative Sleep Disturbance and Anxiety in Patients Undergoing Gastroenteroscopies","Inclusion Criteria:\n\n1. Age 20-65 years old;\n2. ASA classification is grade I-III;\n3. Elective surgery is proposed\n4. BMI of 19-30 kg\u002Fm2;\n5. Patients who agreed to enroll in this study voluntarily\n\nExclusion Criteria:\n\n1. Those who are known to be allergic to the drug ingredients in this study and their allergic constitution;\n2. Allergic history of general anesthesia drugs, opioid drugs, non-steroidal drugs;\n3. History of neurological diseases; History of chronic pain; Drug and alcohol addiction; A long history of opioid use; Opiates were given 48 hours before surgery;\n4. ASA rating of IV or V;\n5. Coronary heart disease, bronchial asthma, severe hypertension, severe blood system dysfunction, liver and kidney function, electrolyte abnormalities;\n6. History of gastrointestinal disease (peptic ulcer, Crohn's disease, ulcerative colitis);\n7. Respiratory insufficiency, respiratory failure;\n8. Patients who refused to use intravenous PCA for analgesia;\n9. Pregnant or lactating women;\n10. BMI\\\u003C18 kg\u002Fm2 or BMI\\>30kg\u002Fm2;\n11. Poor compliance, unable to complete the experiment according to the study plan;\n12. Participants who have participated in clinical trials of other drugs within the last 4 weeks;\n13. Any circumstances deemed unsuitable for inclusion by the researcher for any reason.","ALL","20 Years","65 Years",{"count":89,"type":90},400,"ESTIMATED","INTERVENTIONAL",[93],"NA","To explore the effects of esketamine combined with remimazolam on postoperative sleep disturbance and anxiety in surgical patients undergoing gastroenteroscopies",[96],"Sleep Disturbance",[33,98,99,100],"remimazolam","anxiety","gastroenteroscopy","2024-09-01",{"date":103,"type":104},"2024-09-04","ACTUAL",{"date":106,"type":104},"2023-12-01",{"date":108,"type":90},"2024-12-10",{"name":5,"class":6},1]